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Responding to the threat of urban yellow fever outbreaks 
When in April, 2016, WHO declared the yellow fever 
epidemic in Angola a global threat, it was because yellow 
fever appeared in Luanda, the capital city of Angola, 
causing a rapidly spreading urban outbreak due to the 
massive movement of people to and from the city and easy 
access to international airports, with daily connections 
to Asia, Europe, and the Americas. Nearly 45 years had 
elapsed since a similar urban yellow fever epidemic 
occurred in Angola in 1971 (a smaller one occurred in 
1988); in that interval, urbanisation has increased at 
record rates, with more than 62% of the population now 
living in urban areas.1 For reasons that are still poorly 
understood, the yellow fever virus, which is maintained in 
a transmission cycle involving non-human primates and 
arboreal mosquitoes, crosses into a far more threatening 
human-to-human transmission cycle involving urban 
and domestic Aedes aegypti mosquitoes. The distribution 
of A aegypti is now the widest ever recorded and it is 
extensive in all continents, including parts of North 
America and Europe, with more than 3 billion people at 
risk.2 Urbanisation with resulting increased population 
densities, further enhanced by man-made larval habitats, 
amplifi es A aegypti-transmitted diseases, including those 
caused by the dengue, chikungunya, and Zika viruses.3 
Among these viral infections, yellow fever is of major 
concern because the lethality of this haemorrhagic fever is 
20–50%, rivalling that of Ebola virus disease. Of particular 
concern is that urban yellow fever has the potential for 
rapid spread via international travellers to vulnerable 
countries where A aegypti mosquitoes are present. Indeed, 
for the fi rst time, such spread happened during the Angola 
outbreak when travellers infected with yellow fever in 
Angola entered China between March and April, 2016, 
thereby putting 1·8 billion largely unvaccinated people in 
Asia at risk. Fortunately, no autochthonous cases occurred.
In late 2015 and the fi rst months of 2016, the yellow 
fever outbreak in central Africa had a high reproductive 
rate (4·8 new people infected for every case). Although an 
eff ective vaccine, which protects against infection within 
7–10 days after vaccination, has been available since the 
1930s, implementation of an emergency vaccination 
campaign to contain the rapidly expanding outbreak 
was hampered by limited vaccine supplies and problems 
in the delivery of vaccinations. In such a setting it is 
essential to identify the areas at greatest risk of infection, 
to inform vaccine prioritisation decisions. Consequently, 
the analyses by Moritz Kraemer and colleagues4 reported 
in The Lancet Infectious Diseases provide an important 
contribution with many practical implications. 
Although a WHO working group had previously 
identifi ed a set of mainly ecological criteria relevant to 
the transmission of yellow fever virus and systematically 
applied these criteria to classify areas with risk for 
transmission of yellow fever virus,5 the model developed 
by Kraemer and colleagues adds mobility patterns and 
demographic determinants that govern transmission and 
spread of the virus in the region. The investigators used 
standard logistic models that discriminated districts with 
high risk of invasion from others. Notably, population 
density was a dominant predictive factor for onward 
transmission, corroborating previous fi ndings.6 The spread 
of yellow fever in Angola was driven by high population 
density, including in locations that were distant from the 
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captured diff erent aspects of connectivity and were able 
to infer regular daily commuting patterns, longer-term 
movements, and general human diff usion processes. 
Their gravity model assumed that relative fl ow between 
districts is a log-linear function of the population sizes 
of the districts and the distance between them,7 thereby 
emphasising large population centres such as the 
capital cities Luanda (Angola) and Kinshasa (DR Congo), 
which were the epicentres of the epidemic. A radiation 
model additionally took account of the draw from other 
populations within the same radius of the districts 
considered, as well as the population sizes and distance 
of the origin and destination locations. Models based 
on travel volumes as shown by Kraemer and colleagues 
are increasingly used to predict international spread and 
identify the most vulnerable receiving areas or countries 
for infectious diseases such as infl uenza H1N1,8 polio,9 
dengue,10,11 Zika virus,12–14 and yellow fever,15 and should 
become the basis for similar studies aiming to predict 
regional and international spread.
The modelling techniques used by Kraemer and 
colleagues allowed the analysis of near real-time data 
to inform the control of an ongoing outbreak. If, in mid-
February, the 50 districts with the highest calculated 
probability of infection had been targeted, their model 
would have correctly identifi ed 27 (84%) of the 32 districts 
that were eventually aff ected. This approach, if applied 
in the future, could speed up prioritisation of areas to be 
targeted for rapid deployment of vaccines in the context 
of fi nite resources. However, the Article does not address 
how generalisable to other settings the pattern of spread 
was in this particular outbreak in which urban transmission 
initiated in a major city and radiated outward. Moreover 
the model does not account for the fact that yellow fever 
virus was introduced from Angola into densely populated 
parts of the southern DR Congo without the extent of 
spread seen in Angola. 
Yellow fever virus has caused substantial outbreaks in 
Africa (eg, in The Gambia in 1978–79, Nigeria in 1969, 
and Ethiopia in 1962) where sylvatic mosquito vectors 
have been mainly responsible for inter-human virus 
transmission, and where human population movements, 
population density, and A aegypti distribution have not 
clearly determined the pattern of the epidemic at the 
time. These occurrences emphasise the complex ecology 
of yellow fever and the importance of determining the 
role of specifi c mosquito vectors in each yellow fever 
epidemic. Nevertheless, in an increasingly urbanised 
Africa, application of Kraemer and colleagues’ model 
will allow rapid assessment of the predicted pattern of 
spread and logistical approach to containment. Notably, 
the investigators found that the epidemic in Angola 
slowed around the time that vaccination was initiated 
in February, 2016, or even before it was implemented, 
suggesting that other factors, such as a possible change 
in human behaviour, slowed transmission as word spread 
of the dangers of yellow fever. In a 2013 epidemic of 
dengue in Luanda, mosquito avoidance strategies (such as 
application of mosquito repellent or sleeping under a bed 
net) were associated with reduced infections.16
Urban yellow fever poses a substantial threat and large 
A aegypti-borne outbreaks have occurred despite the 
constrained transmission dynamics resulting from the 
relatively low competence of this vector for yellow fever,17 
the early recognition of the striking clinical presentation, 
and the availability of a safe and effi  cient vaccine. The 
main lesson learned from the recent Angolan yellow fever 
outbreak is that control eff orts should not rely on reactive 
vaccination campaigns, which are always associated with 
delays that result in preventable deaths. The mainstay for 
yellow fever control remains adequate vaccine coverage. 
To achieve high vaccination coverage on a long-term 
basis, the best strategy is to incorporate yellow fever 
vaccination into routine infant immunisations and to 
implement catch up campaigns in the older population. 
To that end, a new eff ort led by WHO (Eliminating Yellow 
fever Epidemics [EYE]) is planned to roll out during the 
next 5 years. Until it is implemented, outbreaks will 
continue to arise from the enzootic cycles, with potential 
spread by urban transmission. 
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Quantifying the fi tness of antiviral-resistant infl uenza strains
Infl uenza remains a serious public health threat, causing 
recurrent outbreaks of respiratory virus infections on 
a global scale every year. Occasional pandemics mark 
the establishment of a novel virus in the population.1 
Vaccination and antiviral treatment can mitigate 
infl uenza morbidity and mortality, particularly among 
high-risk populations.2 However, viral evolution 
promotes escape from population immunity to natural 
infection or vaccination, and facilitates acquisition of 
antiviral resistance. 
The adamantane class of anti virals has been available 
for decades but are no longer used due to frequent 
adverse events and high resistance in circulating viruses. 
Oseltamivir (Tamifl u; Roche, Basel, Switzerland) belongs 
to a newer class of antivirals approved for infl uenza 
treatment and prophylaxis in 1999 in the USA. It was 
believed that oseltamivir resistance came at a high 
fi tness cost for the virus, precluding eff ective onward 
transmission, and hence was not considered an issue. 
This honeymoon period for oseltamivir ended abruptly 
with the rapid global spread and fi xation of resistance 
in infl uenza A H1N1 viruses in 2007–08, including in 
countries that used little or no antivirals.3,4 Several years 
later, experimental studies revealed that compensatory 
mutations had facilitated the rise of resistance.5 In 
2009, the emergence of a pandemic A H1N1 virus 
susceptible to oseltamavir displaced the resident strains, 
conveniently setting a clean slate for oseltamivir use 
against A H1N1 infection. Sporadic emergence of 
resistant A H1N1 viruses since 2009 suggests that 
the threat is still there, and that careful monitoring is 
essential. In The Lancet Infectious Diseases, Kathy Leung 
and colleagues6 introduce a practical statistical method 
to predict the potential of antiviral-resistant strains to 
outcompete susceptible strains, and help re-evaluate 
the arsenal of tools for fi ghting infl uenza in near real 
time.
Leung and colleagues’6 method relies on minimal 
surveillance data on the incidence of resistant and 
susceptible strains and information on the generation 
interval (the interval between successive cases, typically 
well-known for infl uenza) to quantify the relative fi tness 
of the resistant virus over sensitive strains. The method 
is shown using both theoretical simulations and 
empirical data. Simulations show that unbiased fi tness 
estimates are obtained after about ten generations 
of disease transmission when at least fi ve infl uenza 
specimens are tested daily for resistance, and the 
sensitivity and specifi city of the test are greater than 
90%. However, the method is sensitive to assumptions 
about the distribution of the generation interval and 
stochastic eff ects. In applying their method to empirical 
data from ten regions in 2007–08, the authors found 
that the antiviral-resistant strain exhibited, on average, 
a 3–5% higher transmissibility than the susceptible 
virus, in line with a previous global mechanistic 
model.7 However, much heterogeneity in country-level 
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